Core Viewpoint - Waters Corporation reported strong Q2 performance with revenue reaching $771 million, a year-over-year increase of 8.9%, and a sequential increase of 16.6%. The company also announced a transformative acquisition plan for BD, expecting significant value creation through cost and revenue synergies [4][6][16]. Financial Performance - In Q2, Waters' revenue was $771 million (approximately RMB 5.56 billion), with a year-over-year growth of 8.9% and a sequential growth of 16.6%. The growth was primarily driven by the instrument business, which saw a 4% increase at constant currency, with high single-digit growth in liquid chromatography (LC) and mass spectrometry (MS) [6][7]. - The recurring revenue also grew by 11% at constant currency, reflecting strong demand for high-end analytical instruments, particularly in the Chinese biopharmaceutical sector [10][12]. Regional and Segment Performance - Waters experienced significant growth across different regions, with Asia achieving a 14% increase, Europe growing by 8%, and the Americas only increasing by 2% due to a 20% decline in the TA segment [8]. - Notably, the Chinese market showed remarkable performance with revenue of $117 million, a year-over-year increase of 17% and a sequential increase of 28.9%, driven by strong demand for instrument replacements in quality control and new drug development [10][12]. Strategic Initiatives - The company attributed its strong performance to successful execution of business strategies, innovative product launches, and targeted growth plans. The Alliance iS system saw a threefold increase in sales year-over-year, while other innovations like Xevo TQ Absolute+XR and MaxPeak Premier also experienced significant sales growth [15][16]. - Waters announced the acquisition of BD Biosciences & Diagnostic Solutions, positioning it as a transformative move expected to generate $200 million in cost synergies by the third year post-acquisition and $290 million in additional sales by the fifth year [16][17]. Market Concerns - Following the acquisition announcement, Waters' stock price fell by 11.5%, indicating market skepticism regarding the high valuation of $17.5 billion for BD's divested business, which corresponds to a 19x EBITDA multiple, above the industry average of 15x [21][24]. - Concerns also arose regarding the potential challenges of integrating BD's business, given the differences in business models and regulatory environments, which could complicate the realization of expected synergies [26][28]. Conclusion - Waters' Q2 performance reflects robust operational capabilities and a solid foundation for future growth. However, the market's skepticism regarding the integration of BD's business and the realization of synergies poses a significant challenge for the company moving forward [29].

Core Viewpoint - In the fiscal year 2024, Shimadzu achieved record revenue for the fifth consecutive year, reaching 539 billion yen (approximately 26.88 billion RMB), with a year-on-year growth of 5% [1][2]. Financial Performance - Despite the challenging environment in fiscal year 2024, Shimadzu reported a slight decline in net profit by 1% to 71.7 billion yen (approximately 3.58 billion RMB) [2]. - In Q4 of fiscal year 2025, Shimadzu's revenue and profit both reached new highs, with revenue increasing by 6% to 154.8 billion yen (approximately 7.74 billion RMB) and profit rising by 12% to 24.7 billion yen (approximately 1.23 billion RMB) [2]. Regional Market Analysis - Japan remains the most significant revenue source for Shimadzu, accounting for 43.5% of total revenue in fiscal year 2024 [5]. - The Chinese market experienced a decline, with revenue falling by 9% to 91.3 billion yen (approximately 4.56 billion RMB) [5]. Segment Performance - The Analytical and Measuring Instruments segment saw a revenue increase of 3% to 347.9 billion yen (approximately 17.4 billion RMB), but operating profit decreased by 9% to 52.1 billion yen (approximately 2.61 billion RMB) due to rising R&D and labor costs [8]. - Core products (LC, MS, GC) had a global sales increase of 3% to 190.5 billion yen (approximately 9.53 billion RMB), with a 7% growth in regions outside China [9]. Strategic Actions - Facing multiple challenges, including tariffs, rising raw material costs, and increased competition from local brands, Shimadzu forecasts a decline in operating profit for fiscal year 2025 to approximately 515 billion yen (about 25.76 billion RMB) and a 19% drop in net profit to 58 billion yen (approximately 2.9 billion RMB) [11]. - The company plans to enhance the promotion of high-value-added products and adjust sales strategies based on regional tariff impacts [11][12]. - In the U.S. market, Shimadzu will implement short-term price adjustments and increase local inventory, while long-term strategies will focus on optimizing sales through its U.S. production base [11]. Innovation and Future Growth - Shimadzu is celebrating its 150th anniversary and aims to contribute to society through science and technology, focusing on healthcare, green energy, and industrial sectors [16]. - The company is set to launch over 10 new products to enhance performance and provide new value to customers [13].